Literature DB >> 10565921

Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi.

M B Lawrenz1, J M Hardham, R T Owens, J Nowakowski, A C Steere, G P Wormser, S J Norris.   

Abstract

VlsE is a 35-kDa surface-exposed lipoprotein of Borrelia burgdorferi that was shown previously to undergo antigenic variation through segmental recombination of silent vls cassettes with vlsE during experimental mouse infections. Previous data had indicated that sera from North American Lyme disease patients and experimentally infected animals contained antibodies reactive with VlsE. In this study, sera from patients with Lyme disease, syphilis, and autoimmune conditions as well as from healthy controls were examined for reactivity with VlsE by Western blotting and enzyme-linked immunosorbent assay (ELISA). Strong Western blot reactivity to a recombinant VlsE cassette region protein was obtained consistently with Lyme disease sera. Although sera from Lyme disease patients also reacted with a band corresponding to VlsE in B. burgdorferi B31-5A3, interpretation was complicated by low levels of VlsE expression in in vitro-cultured B. burgdorferi and by the presence of comigrating bands. An ELISA using recombinant VlsE was compared with an ELISA using sonically disrupted B. burgdorferi as the antigen. For a total of 93 Lyme disease patient sera examined, the VlsE ELISA yielded sensitivities of 63% for culture-confirmed erythema migrans cases and 92% for later stages, as compared to 61 and 98%, respectively, for the "whole-cell" ELISA. The specificities of the two assays with healthy blood donor sera were comparable, but the VlsE ELISA was 90% specific with sera from syphilis patients, compared to 20% specificity for the whole-cell ELISA with this group. Neither assay showed reactivity with a panel of sera from 20 non-Lyme disease arthritis patients or 20 systemic lupus erythematosus patients. Our results indicate that VlsE may be useful in the immunodiagnosis of Lyme disease and may offer greater specificity than ELISAs using whole B. burgdorferi as the antigen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565921      PMCID: PMC85865     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

Review 1.  Borrelia burgdorferi infection: clinical diagnostic techniques.

Authors:  P K Coyle
Journal:  Immunol Invest       Date:  1997 Jan-Feb       Impact factor: 3.657

2.  Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes.

Authors:  J R Zhang; J M Hardham; A G Barbour; S J Norris
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection.

Authors:  Y Q Zhang; D Mathiesen; C P Kolbert; J Anderson; R T Schoen; E Fikrig; D H Persing
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

Review 4.  Lyme disease.

Authors:  J J Nocton; A C Steere
Journal:  Adv Intern Med       Date:  1995

5.  The persistence of spirochetal nucleic acids in active Lyme arthritis.

Authors:  J F Bradley; R C Johnson; J L Goodman
Journal:  Ann Intern Med       Date:  1994-03-15       Impact factor: 25.391

6.  Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis.

Authors:  J J Nocton; B J Bloom; B J Rutledge; D H Persing; E L Logigian; C H Schmid; A C Steere
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

7.  Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of lyme borreliosis.

Authors:  L A Magnarelli; E Fikrig; S J Padula; J F Anderson; R A Flavell
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

8.  A specific and sensitive assay for the Lyme disease spirochete Borrelia burgdorferi using the polymerase chain reaction.

Authors:  P A Rosa; T G Schwan
Journal:  J Infect Dis       Date:  1989-12       Impact factor: 5.226

9.  High- and low-infectivity phenotypes of clonal populations of in vitro-cultured Borrelia burgdorferi.

Authors:  S J Norris; J K Howell; S A Garza; M S Ferdows; A G Barbour
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Cross-reactivity in serological tests for Lyme disease and other spirochetal infections.

Authors:  L A Magnarelli; J F Anderson; R C Johnson
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

View more
  65 in total

1.  Evidence for the contribution of point mutations to vlsE variation and for apparent constraints on the net accumulation of sequence changes in vlsE during infection with Lyme disease spirochetes.

Authors:  S Y Sung; J V McDowell; R T Marconi
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

2.  Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.

Authors:  Thomas B Ledue; Marilyn F Collins; John Young; Martin E Schriefer
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

3.  Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts.

Authors:  Ashley L Marcinkiewicz; Alan P Dupuis; Maxime Zamba-Campero; Nancy Nowak; Peter Kraiczy; Sanjay Ram; Laura D Kramer; Yi-Pin Lin
Journal:  Cell Microbiol       Date:  2019-01-07       Impact factor: 3.715

4.  Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics.

Authors:  Richard B Porwancher; C Greg Hagerty; Jianqing Fan; Lisa Landsberg; Barbara J B Johnson; Mark Kopnitsky; Allen C Steere; Karen Kulas; Susan J Wong
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

5.  An Update to a Review of Guidelines for the Clinical Laboratory Diagnosis of Lyme Disease.

Authors:  Caterina M Miraglia
Journal:  J Chiropr Med       Date:  2020-12-15

6.  Evaluation of bioMérieux's Dissociated Vidas Lyme IgM II and IgG II as a First-Tier Diagnostic Assay for Lyme Disease.

Authors:  Claudia R Molins; Mark J Delorey; Adam Replogle; Christopher Sexton; Martin E Schriefer
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

7.  A Fully Automated Multiplex Assay for Diagnosis of Lyme Disease with High Specificity and Improved Early Sensitivity.

Authors:  Johnnie B Hahm; John W Breneman; Jing Liu; Svetlana Rabkina; Weiming Zheng; Shuxia Zhou; Roger P Walker; Ravi Kaul
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

8.  BBK07, a dominant in vivo antigen of Borrelia burgdorferi, is a potential marker for serodiagnosis of Lyme disease.

Authors:  Adam S Coleman; Utpal Pal
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

9.  Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease.

Authors:  Gary P Wormser; Martin Schriefer; Maria E Aguero-Rosenfeld; Andrew Levin; Allen C Steere; Robert B Nadelman; John Nowakowski; Adriana Marques; Barbara J B Johnson; J Stephen Dumler
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-11       Impact factor: 2.803

10.  Central role of the Holliday junction helicase RuvAB in vlsE recombination and infectivity of Borrelia burgdorferi.

Authors:  Tao Lin; Lihui Gao; Diane G Edmondson; Mary B Jacobs; Mario T Philipp; Steven J Norris
Journal:  PLoS Pathog       Date:  2009-12-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.